君实生物子公司通过美国FDA现场检查

Core Viewpoint - Junshi Biosciences announced that its wholly-owned subsidiary, Suzhou Zhonghe Biopharmaceutical Technology Co., Ltd., successfully passed a CGMP inspection by the FDA, indicating compliance with current good manufacturing practices [1] Group 1 - The FDA conducted an unannounced CGMP inspection from June 16 to June 24, 2025 [1] - Suzhou Zhonghe received a report from the FDA confirming the successful completion of the CGMP inspection [1]